key: cord-0775389-hy8rjgry
authors: Sung, Heungsup; Yoo, Cheon-Kwon; Han, Myung-Guk; Lee, Sang-Won; Lee, Hyukmin; Chun, Sail; Lee, Wee Gyo; Min, Won-Ki
title: Preparedness and Rapid Implementation of External Quality Assessment Helped Quickly Increase COVID-19 Testing Capacity in the Republic of Korea
date: 2020-04-22
journal: Clin Chem
DOI: 10.1093/clinchem/hvaa097
sha: 5fdafa99717f766cbcb722b04f87b794c3d1d06f
doc_id: 775389
cord_uid: hy8rjgry

nan

To the Editor:

The current outbreak of coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus 2, continues to spread, and as of March 31, 2020, it has reached 200 countries, with 785,219 cases and 37,797 deaths (1). Since the first case was reported in the Republic of Korea on January 19, 2020, more than 9,500 confirmed cases had been identified by March 31. Since March 2, the number of newly-reported cases appeared to have been declining, and the reported cases have been mostly related to certain provinces. As of March 31, the Republic of Korea (population of 51 million) was testing more than 20,000 patients per day. Clinical pathologists and microbiologists of other countries wonder how our nation rapidly expanded its capacity for COVID-19 testing in such a short period. The key factors in this rapid expansion of testing capacity were the establishment of an emergency use authorization (EUA) system, an external quality assessment (EQA), and the collaboration between the public and private sectors. The KEQAS was responsible for transporting the EQA material, collecting the EQA results, and judging the results. Only samples with an 80% or more agreement rate compared to the expected results were evaluated. Approval for COVID-19 molecular testing was given when a laboratory had correctly answered all the evaluable results. By February 6, the KEQAS had certified 46 out of the 47 laboratories that entered the results. Forty-six non-governmental clinical laboratories were able to begin COVID-19 testing using a commercial EUA kit from February 7. Due to high testing demand at the beginning, testing complied with the inclusion criteria. The COVID-19 real-time RT-PCR is indicated for confirmation of suspected COVID-19 patients who present with fever (37.5 or higher) and/or respiratory symptoms (cough, sore throat, etc.) and history of close contact with a confirmed individual within the previous 14 days. It is also indicated for screening of asymptomatic individuals in close contact with confirmed COVID-19 patients and for differential diagnosis of cases with unknown respiratory syndromes (5) . There are no specific exclusion criteria for testing, although testing done outside the criteria are denied of national healthcare system reimbursement for the testing fee. Two more EQAs using the same plasmid DNAs were conducted and 49 additional non-governmental clinical laboratories were enrolled. We have finished the EQA using the inactivated cultured SARS-CoV-2 spiked into pooled respiratory samples.

As of March 31, a total of 95 non-governmental clinical laboratories are conducting more than 20,000 COVID-19 tests per day using five different EUA kits. The five EUA kits' output reached 20,000 kits per week, covering a total of 350,000 clinical samples.

In conclusion, preparedness and rapid implementation of EQA have supported the rapid expansion of COVID-19 testing capacity in the Republic of Korea. Owing to the increasing diagnostic capacity, our nation was able to slow down the COVID-19 epidemic without enforcing city-wide lockdowns or collapse of the national healthcare system. The quality of COVID-19 diagnostic testing was ensured by the KLAP and the EQA programs. 

Middle East Respiratory Syndrome coronavirus outbreak in the Republic of Korea

Food & Drug Administration. Emergency Use Authorization

External quality assessment of molecular diagnostics for Zika virus and Middle East Respiratory Syndrome coronavirus in Korea

Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea